Overview
ICH was established in 1990 and has since facilitated professionals from the three global regions (EU Japan and USA) to formulate appropriate practice guidelines. The rationale behind its formation was the growing understanding within scientific communities that the goals of pharmacovigilance services would be better met if there existed a greater degree of uniformity regarding testing and safety regulations across the different regions.
As an essential part of patient safety, pharmacovigilance is of worldwide interest and should expand its scope and focus on new emerging issues. The change in pharmacovigilance paradigm is a global trend and Korea has excellent infrastructure and in the near future the paradigm of pharmacovigilance will shift in Korea.Program Committee
-
Kyung Won Seo Director General, National Institute of Food and Drug Safety Evaluation
Ministiry of Food and Drug Safety, Korea, Republic of -
Chul Kim, MD, PhD Vice President
Samsung Bioepis, Korea, Republic of -
Seungjae Baek Excutive Director
Hanmi Pharmaceuticals, Korea, Republic of -
Junjeong Choi Associate Professor- Department of Pharmacy
Yonsei University College of Pharmacy, Korea, Republic of -
Sanghee Kim Chief Executive Officer
Novotech Asia Korea Ltd., Korea, Republic of -
MinJung Lim, MPharm Managing director
MediSafe, Pharmacovigilance Services, Korea, Republic of -
Yongseok Ko Deputy Director NIFDS
Ministry of Food and Drug Safety (MFDS), Korea, Republic of -
Eunah Paek Head of Medical Operation Group
Boryung Pharmaceutical Company, Korea, Republic of -
SuWon Kim Pharmacovigilance Manager
Dong-A-ST, Korea, Republic of -
HyeYoung Kim Medical Information & Pharmacoviglance
Chong Kun Dang Pharm, Korea, Republic of -
Mijeong Kim, PhD Medical advisor
C&R Research Inc., Korea, Republic of -
SoYeon Park Senior Drug Safety Manager
Celgene, Korea, Republic of -
Hwayoung Lee Team Lead APAC
Pfizer Pharmaceuticals, Korea, Republic of
Have an account?